A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Maeng, Chi Hoon | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Zang, Dae Young | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.contributor.author | Chung, Joo Seop | - |
dc.contributor.author | Song, Hong Suk | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Jeong, Su Jin | - |
dc.contributor.author | Cho, Jae Yong | - |
dc.date.accessioned | 2021-09-01T22:29:55Z | - |
dc.date.available | 2021-09-01T22:29:55Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-01 | - |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/68819 | - |
dc.description.abstract | Lessons Learned Irinotecan could not be proven noninferior to paclitaxel as a second-line treatment for patients with metastatic or recurrent gastric cancer. The failure to demonstrate noninferiority may have been a result of insufficient patient enrollment. Both agents were tolerable but showed different toxicity profiles. Background This phase III study compared the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer (MRGC) who had experienced disease progression following first-line chemotherapy. Methods Patients were randomized to receive either paclitaxel (70 mg/m(2); days 1, 8, 15, every 4 weeks) or irinotecan (150 mg/m(2) every other week). The primary endpoint was progression-free survival (PFS). Results This study was stopped early due to low accrual rate. A total of 112 patients were enrolled; 54 were allocated to paclitaxel and 58 to irinotecan. Median PFS for the paclitaxel and irinotecan groups was 3.5 and 2.1 months, respectively (hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.86-1.88; p = .234). Noninferiority of irinotecan to paclitaxel was not proved because the upper boundary of the 95% CI (1.88) exceeded the predefined upper margin of noninferiority (1.32). Median overall survival (OS) was 8.6 months in the paclitaxel group and 7.0 months in the irinotecan group (HR, 1.39; 95% CI, 0.91-2.11; p = .126). Among toxicities greater than or equal to grade 3, neutropenia (11.5%) was the most common, followed by peripheral neuropathy (7.7%) in the paclitaxel group, and neutropenia (34.5%) followed by nausea, vomiting, and anemia (8.6%, respectively) in the irinotecan group. Conclusion Although paclitaxel showed numerically longer PFS and OS compared with irinotecan, this was statistically insignificant. Both irinotecan and paclitaxel are valid second-line treatment options in MRGC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | 2ND-LINE CHEMOTHERAPY | - |
dc.subject | SUPPORTIVE CARE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | OPEN-LABEL | - |
dc.subject | PLUS | - |
dc.subject | FLUOROURACIL | - |
dc.subject | COMBINATION | - |
dc.subject | CISPLATIN | - |
dc.subject | DOCETAXEL | - |
dc.subject | FAILURE | - |
dc.title | A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.identifier.doi | 10.1634/theoncologist.2018-0142 | - |
dc.identifier.scopusid | 2-s2.0-85054806347 | - |
dc.identifier.wosid | 000455119900006 | - |
dc.identifier.bibliographicCitation | ONCOLOGIST, v.24, no.1, pp.18 - + | - |
dc.relation.isPartOf | ONCOLOGIST | - |
dc.citation.title | ONCOLOGIST | - |
dc.citation.volume | 24 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 18 | - |
dc.citation.endPage | + | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Data Paper | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | 2ND-LINE CHEMOTHERAPY | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | PLUS | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | FAILURE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.